<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02421380</url>
  </required_header>
  <id_info>
    <org_study_id>14-205</org_study_id>
    <nct_id>NCT02421380</nct_id>
  </id_info>
  <brief_title>Characterization of Hyperpolarized Pyruvate MRI Reproducibility</brief_title>
  <official_title>Characterization of Hyperpolarized Pyruvate MRI Reproducibility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to test a new approach to see if the test results can be&#xD;
      reproduced each time the Magnetic resonance imaging (MRI) is done for an individual patient.&#xD;
      The study will explore the use of an imaging agent called hyperpolarized [1-13C] pyruvate&#xD;
      (HP) with MRI scans. (MRI) is a technique that takes pictures of the body's organs using a&#xD;
      magnetic field and radiofrequency waves that cannot be felt. In order to accomplish the goal&#xD;
      of the study the patient will have two hyperpolarized MRI scans to assess if scans can be&#xD;
      reproduced. The hyperpolarized MRI scans will be compared with the pathological results of&#xD;
      the surgery to see if the hyperpolarized MRI provides additional information regarding&#xD;
      disease metabolism.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>validate HP MRI at MSKCC (are the scans able to be reproduced)</measure>
    <time_frame>1 year</time_frame>
    <description>The imaging will include standard T2-weighted, diffusion-weighted (DW), dynamic contrast-enhanced (DCE) and 1H MR spectroscopic imaging, depending on the solid tumor type. This multi-parametric data will be used to delineate the tumor as well as compare to HP MRI.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">109</enrollment>
  <condition>Malignant Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Hyperpolarized Pyruvate MRI Reproducibility</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a reproducibility study of hyperpolarized [1-13C] pyruvate MRI in patients with solid tumors. A total of 100 patients will be enrolled, 50 of whom will be imaged using 1D MR spectroscopy and the other 50 with 3D imaging sequence.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperpolarized Pyruvate</intervention_name>
    <arm_group_label>Hyperpolarized Pyruvate MRI Reproducibility</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with history of histologically-confirmed malignant solid tumor (histology&#xD;
             confirmed by MSKCC Department of Pathology.) NOTE: An exception will be made for&#xD;
             patients with brain lesions. Patients identified by a radiologist to have a brain&#xD;
             lesion with high suspicion for neoplasm given MRI features will be enrolled, prior to&#xD;
             histological confirmation.&#xD;
&#xD;
          -  Disease measurable or evaluable as defined by RECIST 1.1, a mass of greater than 1cm&#xD;
             in the long axis and/or other tumor response criteria from an MSKCC IRB-approved&#xD;
             clinical research protocol. NOTE: Study patients do not need to be participating in an&#xD;
             MSKCC approved clinical trial prior to study recruitment.&#xD;
&#xD;
          -  Negative serum or urine pregnancy test for female patients of childbearing age and&#xD;
             potential (as defined by MSKCC Standards &amp; Guidelines), from assays obtained &lt; 2 weeks&#xD;
             prior to study enrollment.&#xD;
&#xD;
          -  This study will include only patients with sarcoma, prostate, breast, brain,&#xD;
             metastatic or pancreatic cancer. In the future other patient groups may be included&#xD;
             through amendment of this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability or refusal to have at least one peripheral intravenous line for intravenous&#xD;
             access (as applicable to the day of [1-13C] pyruvate injection)&#xD;
&#xD;
          -  Breast-feeding&#xD;
&#xD;
          -  Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)&#xD;
&#xD;
          -  Hepatic: from assays obtained within 3-4 weeks prior to study enrollment. For each&#xD;
             patient, the upper limit of normal (ULN) value for a particular assay will be defined&#xD;
             by the normal reference values of the laboratory that performed the assay&#xD;
&#xD;
          -  Bilirubin &gt; 1.5 x (ULN)&#xD;
&#xD;
          -  AST/ALT &gt;2.5 x ULN&#xD;
&#xD;
          -  Albumin &lt; 3 g/dl&#xD;
&#xD;
          -  GGT &gt; 2.5 x ULN if Alkaline phosphatase &gt; 2.5 x ULN.&#xD;
&#xD;
          -  Renal: Creatinine &gt;1.5 x ULN or creatinine clearance &lt; 60 mL/min, from assays obtained&#xD;
             within 3-4 weeks prior to study enrollment&#xD;
&#xD;
          -  Acute major illness (e.g., unstable cardiovascular condition, etc.)&#xD;
&#xD;
          -  Standard MRI exclusion criteria will also be applied, including pacemakers and metal&#xD;
             clips located in the patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kayvan Keshari, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kayvan Keshari, PhD</last_name>
    <phone>646-888-3631</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hedvig Hricak, MD, PhD</last_name>
    <phone>212-639-7284</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayvan Keshari, PhD</last_name>
      <phone>646-888-3631</phone>
    </contact>
    <contact_backup>
      <last_name>Hedvig Hricak, MD, PhD</last_name>
      <phone>212-639-7284</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 13, 2015</study_first_submitted>
  <study_first_submitted_qc>April 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2015</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperpolarized Pyruvate</keyword>
  <keyword>MRI</keyword>
  <keyword>14-205</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

